P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab.
Nabin Raj KarkiAbdullah KutlarPublished in: Journal of pain research (2021)
Microvascular vaso-occlusion driven pain crisis is the hallmark of sickle cell disease with profound morbidity and increased mortality. Selectins, most notably P-selectins have an integral role in this phenomenon. P-selection was first identified in 1989. In 2019, after 3 decades of basic, translational, and clinical work with this pathway, the US Food and Drug Administration approved a P-selectin antibody, crizanlizumab to reduce frequency of pain crisis in patients more than 16 years with sickle cell disease. We review the fundamentals of P-selectin pathobiology, P-selectin blocking agents, clinical data with the use of crizanlizumab and prospects of this novel class of drugs in the context of other treatments for painful vaso-occlusive episodes.
Keyphrases
- sickle cell disease
- drug administration
- chronic pain
- public health
- end stage renal disease
- pain management
- neuropathic pain
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- type diabetes
- prognostic factors
- electronic health record
- cardiovascular disease
- cardiovascular events
- risk factors
- coronary artery disease
- patient reported outcomes
- spinal cord
- machine learning
- deep learning
- postoperative pain
- patient reported
- spinal cord injury
- human health